Contrary to declarations by Moffitt Cancer Center, Thomas Sellers, the institution’s ousted director, was not involved in the Thousand Talents program sponsored by the People’s Republic of China, said a Florida attorney who represents Sellers in preparing a lawsuit against the cancer center.
The FDA Oncologic Drugs Advisory Committee July 25 voted unanimously to set more rigorous standards for new trials for approval of perioperative indications of cancer drugs.
